CARDIFF ONCOLOGY INC. - COMMON STOCK

Cardiff Oncology Prices Oversubscribed $40 Million Underwritten Registered Direct Offering

10 Dec 2024 06:20:00 By Nasdaq GlobeNewswire

Cardiff Oncology Announces Positive Initial Data from First-line RAS-mutated mCRC Clinical Trial

10 Dec 2024 05:00:00 By Nasdaq GlobeNewswire

Cardiff Oncology Announces New Patent with Claims for the Use of Onvansertib in Treating KRAS mutated mCRC

19 Nov 2024 07:00:01 By Nasdaq GlobeNewswire

Cardiff Oncology Reports Third Quarter 2024 Results and Provides Business Update

07 Nov 2024 15:05:00 By Nasdaq GlobeNewswire

Cardiff Oncology Announces Journal of Clinical Oncology Publication of Data from Phase 2 Trial in Second-line KRAS Mutant mCRC

30 Oct 2024 15:30:00 By Nasdaq GlobeNewswire

Cardiff Oncology Reports Second Quarter 2024 Results and Provides Business Update

08 Aug 2024 15:05:01 By Nasdaq GlobeNewswire

Cardiff Oncology to Report Second Quarter 2024 Results and Provide Business Update

01 Aug 2024 15:05:00 By Nasdaq GlobeNewswire

Cardiff Oncology to Present at the Jefferies Healthcare Conference

29 May 2024 15:05:00 By Nasdaq GlobeNewswire

Cardiff Oncology to Present at Upcoming Investor Conferences in May

13 May 2024 15:05:00 By Nasdaq GlobeNewswire

Cardiff Oncology Reports First Quarter 2024 Results and Provides Business Update

02 May 2024 15:05:00 By Nasdaq GlobeNewswire

Cardiff Oncology to Report First Quarter 2024 Results and Provide Business Update

25 Apr 2024 15:05:00 By Nasdaq GlobeNewswire

Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study

08 Apr 2024 15:05:00 By Nasdaq GlobeNewswire

Cardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2024

06 Mar 2024 15:05:00 By Nasdaq GlobeNewswire

Cardiff Oncology Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update

29 Feb 2024 15:07:00 By Nasdaq GlobeNewswire

Cardiff Oncology Provides Clinical Update on Phase 2 Randomized Second-line ONSEMBLE Trial in Patients with RAS-mutated mCRC

29 Feb 2024 15:06:00 By Nasdaq GlobeNewswire

Cardiff Oncology Announces First Patient Dosed in Randomized First-line RAS-mutated Metastatic Colorectal Cancer Trial (CRDF-004)

29 Feb 2024 15:05:00 By Nasdaq GlobeNewswire

Cardiff Oncology to Present at the Cowen 44th Annual Health Care Conference

26 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

Cardiff Oncology to Report Fourth Quarter and Full Year 2023 Results and Provide Business Update

22 Feb 2024 07:00:00 By Nasdaq GlobeNewswire